Gilead Sciences, Inc. (GILD) Analysts See $1.59 EPS

April 17, 2018 - By Jimmy Baldridge

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It turned negative, as 95 investors sold Gilead Sciences, Inc. shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported.
Spears Abacus Advsrs Limited Com stated it has 313,455 shares. Ci Investments Inc owns 3.32M shares for 4.58% of their portfolio. Moreover, Penobscot Inv Management has 0.14% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 7,050 shares. Nordea Invest Mngmt Ab owns 935,882 shares. Zacks Investment owns 0.85% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 544,382 shares. General Co Inc invested in 443,600 shares. Alpine Woods Cap Invsts Limited Liability Corporation reported 0.02% in Gilead Sciences, Inc. (NASDAQ:GILD). Tctc Holding Ltd Liability Corp accumulated 4,783 shares. Girard Ltd holds 0.3% in Gilead Sciences, Inc. (NASDAQ:GILD) or 21,504 shares. Thornburg Invest Mngmt Incorporated has invested 0.62% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Burns J W & New York reported 26,666 shares. Chickasaw Capital Ltd Co invested in 0.03% or 22,100 shares. Ing Groep Nv stated it has 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Jane Street Group Limited Com, New York-based fund reported 314,602 shares. Paloma Prtnrs Mgmt reported 6,261 shares.

Since January 2, 2018, it had 0 insider purchases, and 17 insider sales for $39.51 million activity. MARTIN JOHN C also sold $3.66M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, April 2. Cogan John Francis had sold 5,833 shares worth $434,384. Shares for $401,566 were sold by Washington Robin L on Wednesday, February 21. Meyers James R had sold 100,000 shares worth $8.02M on Tuesday, January 16. WILSON GAYLE E sold $4.68M worth of stock.

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report $1.59 EPS on May, 1.They anticipate $0.61 EPS change or 27.73 % from last quarter’s $2.2 EPS. GILD’s profit would be $2.07 billion giving it 11.74 P/E if the $1.59 EPS is correct. After having $1.60 EPS previously, Gilead Sciences, Inc.’s analysts see -0.63 % EPS growth. The stock decreased 0.70% or $0.53 during the last trading session, reaching $74.69. About 4.24 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 17, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 15 analysts covering Gilead Sciences (NASDAQ:GILD), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Gilead Sciences had 27 analyst reports since October 19, 2017 according to SRatingsIntel. Mizuho maintained it with “Buy” rating and $77.0 target in Sunday, October 29 report. Citigroup upgraded the stock to “Buy” rating in Tuesday, January 30 report. The firm has “Buy” rating given on Monday, February 12 by Mizuho. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Thursday, November 30 by Maxim Group. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, October 27 report. The rating was maintained by Mizuho with “Buy” on Monday, February 5. The firm earned “Hold” rating on Thursday, February 22 by Leerink Swann. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, February 7 by RBC Capital Markets. The rating was maintained by Leerink Swann on Wednesday, February 7 with “Market Perform”. The rating was downgraded by Credit Suisse to “Neutral” on Wednesday, December 20.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $97.39 billion. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 21.28 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: